Update on the treatment of focal segmental glomerulosclerosis in renal transplantation by Messina, Maria et al.
Update on the treatment of focal segmental 
glomerulosclerosis in renal transplantation
Maria Messina, Ester Gallo, Alberto Mella, Fabiola Pagani, Luigi Biancone
Maria Messina, Ester Gallo, Alberto Mella, Fabiola Pagani, 
Luigi Biancone, Renal Transplantation Center “A. Vercellone”, 
Division of Nephrology Dialysis and Transplantation, Department 
of Medical Sciences, Città della Salute e della Scienza Hospital 
and University of Turin, 10126 Turin, Italy
Author contributions: Messina M, Gallo E, Mella A, Pagani F 
and Biancone L equally contributed to conception and design of 
the study, literature review, and analysis, drafting, critical revision 
and editing of the manuscript; all authors approved the final 
version.
Conflict-of-interest statement: None of the authors has any 
potential conflicts of interest related to this study.
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Correspondence to: Luigi Biancone, MD, PhD, Renal 
Transplantation Center “A. Vercellone”, Division of Nephrology 
Dialysis and Transplantation, Department of Medical Sciences, 
Città della Salute e della Scienza Hospital and University of 
Turin, Corso Bramante 88, 10126 Turin, 
Italy. luigi.biancone@unito.it
Telephone: +39-011-6336797
Fax: +39-011-6334990
Received: November 15, 2015
Peer-review started: November 16, 2015
First decision: December 7, 2015
Revised: December 22, 2015 
Accepted: January 21, 2016 
Article in press: January 22, 2016
Published online: March 24, 2016
Abstract
Focal segmental glomerulosclerosis (FSGS) represents 
one of the most severe glomerular diseases, with 
frequent progression to end-stage renal disease and a 
high rate of recurrence in renal allografts (30%-50%). 
Recurrent FSGS portends a negative outcome, with 
the hazard ratio of graft failure being two-fold higher 
then that of other glomerulonephritis. Two patterns of 
clinical presentations are observed: Early recurrence, 
which is characterized by massive proteinuria within 
hours to days after implantation of the renal graft, 
and late recurrence, which occurs several months or 
years after the transplantation. Many clinical conditions 
have been recognized as risk factors for recurrence, 
including younger age, rapid progression of the disease 
to end-stage renal disease on native kidneys, and 
loss of previous renal allografts due to recurrence. 
However, much less is known about the incidence and 
risk factors of the so-called “de novo ” type of FSGS, 
for which sufferers are transplanted patients without 
disease on native kidneys; but, rapid development of 
allograft failure is frequently observed. Management 
of both forms is challenging, and none of the ap-
proaches proposed to date have been demonstrated 
as consistently beneficial or effective. In the present 
review we report an update on the available therapeutic 
strategies for FSGS in renal transplantation within the 
context of a critical overview of the current literature.
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Core tip: Focal segmental glomerulosclerosis (FSGS) 
presents as a histological pattern of kidney damage 
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with different, multifactorial, and often undefined 
pathogenesis. Primary FGSS represents one of the most 
severe glomerular diseases, with frequent progression 
to end-stage renal failure and a high rate of recurrence 
in renal allografts. FSGS recurrence also portends a 
negative outcome. Despite the proposal of multiple 
therapeutic approaches, none has emerged as the 
resolutive option. This review provides an update on 
the currently available therapeutic strategies for FSGS 
in renal transplantation, along with a critical overview 
of the related literature.
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INTRODUCTION
Focal segmental glomerulosclerosis (FSGS) presents as 
a histological pattern of kidney damage with different, 
multifactorial, and frequently undefined pathogenesis. 
FSGS represents one of the most serious glomerular 
diseases, with frequent progression to end-stage 
renal disease and a high rate of recurrence in renal 
allografts. Clinical classification includes the following 
five forms[1]: Primary or idiopathic FSGS, the etiology 
of which is largely unknown; secondary or adaptive 
FSGS, which commonly refers to an adaptive response 
to glomerular hypertrophy/hyperfiltration and which 
presents a nonspecific pattern of scarring due to a 
previous injury; genetic FSGS; drug-induced FSGS; 
virus-associated FSGS.
In renal transplanted patients, both primary and 
secondary FSGS are observed. For the primary form, 
recurrent and de novo types are more severe. Obtaining 
an accurate estimation of de novo FSGS occurrence, 
however, is challenging because of the high rate of renal 
diseases of unknown cause in native kidneys (15.6% 
and 18.2% in the OPTN-SRTR annual report and ERA-
EDTA registry, respectively)[2,3]. FSGS recurrence occurs 
frequently after transplantation, with reported rates 
ranging from 30% to 50%[4-6]. The risk of recurrence 
is substantially higher (up to nearly 100%) in patients 
who lost their first graft due to a recurrence[7]. 
Recurrent FSGS portends a negative outcome, with the 
hazard ratio (HR) of kidney failure being 2.03 compared 
to other kinds of recurrent glomerulonephritis[8]. Two 
patterns of clinical presentations are observed: Early 
recurrence, which is most commonly encountered 
in pediatric patients and characterized by a massive 
proteinuria that occurs within hours to days after 
implantation of the new kidney; late recurrence, which 
often develops insidiously at several months to years 
after the transplantation[9].
Many clinical conditions have been recognized as 
risk factors for recurrence[4,8,10], including younger 
age (particularly in children who were > 6-year-old 
at FSGS onset), mesangial proliferation in the native 
kidneys, rapid progression of the disease to end-
stage renal disease (ESRD; < 3 years from onset) for 
native kidneys, pre-transplant bilateral nephrectomy, 
non-African race, specific genetic background, heavy 
proteinuria before transplantation, and, as cited above, 
loss of previous allografts due to recurrence.
Update on pathogenetic mechanisms
Several lines of evidence have suggested that pro-
teinuria and glomerular histologic alterations can be 
mediated by the direct activity of a circulating factor. 
These data were obtained from ex vivo analysis of 
glomerular changes after incubation with serum from 
patients with FSGS, as firstly described by Sharma 
et al[11] in 1999, as well as from analysis of animal 
models in which kidneys from a specific line of affected 
mice showed recovery from FSGS after transplantation 
into normal mice[12]. The most striking data, however, 
was obtained from a study of a kidney with FSGS 
recurrence that had been re-grafted from a patient to 
another and led to total regression of the disease[13]. 
However, identification of the responsible factor(s) is 
still a matter of investigation, although some different 
molecules are considered likely candidates.
In recent years research interest has focused on 
the soluble form of the urokinase type plasminogen 
activator receptor (suPAR). suPAR appears to be able 
to cause podocyte foot effacement in mice[14], and 
suPAR levels observed in patients with FSGS are higher 
than those in patients with other glomerulopathies[15]. 
Nevertheless, the specific involvement of suPAR in 
glomerulonephritis has not been confirmed by other 
studies, which showed increased (plasma) suPAR 
levels in other pathological situations (i.e., bacterial 
and viral infections, sepsis, and cancer)[16]. Rather, 
increased suPAR levels were observed primarily in 
patients with reduced glomerular filtration rate (GFR), 
suggesting that an elevation of suPAR levels may 
merely be an indicator of reduced GFR[17]. Finally, the 
usefulness of suPAR to distinguish between FSGS and 
non-FSGS glomerulonephritis has been questioned 
by Bock et al[18], who showed similar (plasma) suPAR 
levels among FSGS patients, non-FSGS controls, and 
healthy volunteers.
Other circulating factors, such as cardiothropin-
like cytokine 1 (CLC-1), vasodilator-stimulated 
phosphoprotein and apolipoprotein A-I, have also been 
proposed as effectors in the glomerular permeability 
process, but their clinical and pathological roles 
remain unknown[19]. Recently, detection of a panel of 
serum antibodies directed towards podocyte antigens 
was found to be associated with a high percentage 
of relapses in FSGS (predictive recurrence value of 
92%)[20]. The most prominent of these antigens is 
CD40; the expression of which is up-regulated in 
podocytes in FSGS, supporting the hypothesis of 
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a potential direct pathogenetic effect of anti-CD40 
antibodies.
Demonstration of the precise permeability factor(s) 
remains elusive. Yet, recent findings have confirmed the 
critical role played by podocytes in FSGS development, 
and different podocyte antigens/cellular pathways have 
been associated with the disease course and medical 
treatment response (Figure 1). For example, it has 
been postulated that the B71 and sphingomyelin-
phosphodiesterase-acid-like-3b (SMLPD-3b) proteins 
(both of which are expressed on the podocyte mem-
brane) may directly interact with the cytoskeleton-
inducing foot process effacement in response to a 
permeability factor[21,22]; interestingly, this effect could 
be antagonized by some drugs recently adopted in 
FSGS treatment [abatacept (Orencia®)/belatacept 
(Nulojix®)] for B71 and Rituximab® for SMLPD-3b, in 
particular), as outlined below in the therapeutic section.
Drug-induced or genetic-related alterations of 
the podocyte metabolic pathways may also lead to a 
maladaptive response to cell injury, defining a “pro-
FSGS” phenotype, as has been observed in some 
patients with specific donor APOL1 polymorphisms[23] 
or in animal models with inhibition of the mTOR/Akt 
axis[24].
Another step forward in defining this disease may 
be achieved upon increasing our knowledge of the 
influence of micro (mi)RNAs on podocyte activity. 
In a mouse model, Gebeshuber et al[25] observed 
that transgenic expression of miR-193a (a down-
regulator of WT1, itself a crucial effector in podocyte 
homeostasis) rapidly induces FSGS and observed up-
regulated expression of miR-193a in isolated glomeruli 
from individuals with FSGS, as compared to kidney 
levels in healthy individuals or individuals with other 
glomerular diseases. 
In addition to the probably pivotal role of podocytes 
in the disease process, it is also likely that T and 
B cells of the immune system contribute to FSGS 
development. A Th2 phenotype is commonly observed 
in patients with idiopathic nephrotic syndrome (NS)[26], 
and overexpression of IL-13, a characteristic Th2 
cytokine, is associated with significant proteinuria 
in Wistar rats[27]. An indirect confirmation of B cell 
involvement derives from evidence showing a selective 
Rituximab®-induced depletion is correlated to disease 
remission[28]. This association has recently been 
questioned, however, so the role of B cells in FSGS 
pathogenesis is still not well defined.
OVERVIEW OF CURRENT FSGS 
TREATMENTS
FSGS treatment in renal transplantation, both for 
recurrent and de novo types, is a significant clinical 
challenge. Unfortunately, most of the reports consist 
of few cases or even a single case. Studies of the 
available strategies are few and have shown unclear 
and conflicting results for each, possibly due to their 
retrospective nature, uncontrolled design and limited 
number of enrolled patients or short follow-up periods. 
Consequently, while experimental studies have pro-
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Figure 1  Evolution of the therapeutic approaches for focal segmental glomerulosclerosis recurrence and related recent perspectives. The various treatments 
and their mechanisms are represented by the star shapes. CyA: Cyclosporine; PE: Plasma exchange; MMF: Mycophenolate mofetil; suPAR: Soluble form of the 
urokinase type plasminogen activator receptor; CYC: Cyclophosphamide; RTX: Rituximab®; IA: Immuno-adsorption; Synpo: Synaptopodine; SMLPD-3b: Sphingomyelin-
phosphodiesterase-acid-like-3b protein. Note: Steroids also regulate the podocyte activity of stabilizing the actin cytoskeleton, preserving glomerular permeselectivity, 
and directly reducing apoptosis via the PI3K/Akt signaling pathway.
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proteinuria after post-transplant year 1, concurrent to 
PE frequency reduction, had been successfully treated 
with Rituximab® (2 doses) and PE sessions bimonthly, 
obtaining a complete proteinuria remission in the 34 ± 
6.7 mo of follow-up.
A positive effect is also described for plasma 
absorption in some papers[34-37], but further studies 
are needed to define the potential additive benefit in 
comparison with PE.
Glucocorticoids
KDIGO guidelines suggest for FSGS on native kidneys 
a 4-wk to 16-wk course of prednisone (1 mg/kg per 
day, with a maximum of 80 mg and a slow tapering in 
the 6 mo after remission)[38]. Glucocorticoids may act 
to stabilize the actin cytoskeleton, thereby preserving 
glomerular permeselectivity[39] and directly reducing 
podocyte apoptosis via the PI3K/Akt signal pathway[40]. 
Efficacy of steroid treatment in recurrent/de novo 
FSGS has never been evaluated in a randomized trial; 
on the other hand, considering its pivotal therapeutic 
role in FSGS on native kidneys, many different 
regimens have included steroids in post-transplantation 
FSGS treatment.
Apart from the paper by Canaud et al[33], who 
described a combined treatment of CyA in associa-
tion with high dose steroids and PE, Shishido et 
al[41] also reported a favorable outcome (7/10 com-
plete remission) for pediatric patients with FSGS 
recurrence in response to a combined treatment with 
methylprednisolone pulses (20 mg/kg after diagnosis 
on 3 consecutive days in weeks 1, 3 and 5) and an 
increase in CyA target levels (area under the curve0–4 
4500-5500 ng/h per milliliter for the first month, 4000 
ng/h per milliliter for the next 2 mo, and 3000 ng/h per 
milliliter thereafter).
Cyclosporine 
CyA is commonly applied for the treatment of several 
immune-mediated diseases and as a second-line 
therapy for steroid-resistant/dependent FSGS on 
native kidneys[38]. Conversely, CyA does not appear 
to prevent post-transplant FSGS recurrence when 
given as a part of the initial immunosuppressive re-
gimen[42,43]; although, this potential has not been 
evaluated in more recent studies. Standard oral 
doses of CyA have not been associated with reduced 
incidence of recurrent FSGS. Nonetheless, higher 
intravenous doses have been associated with remission 
of proteinuria for the first time since reported by Ingulli 
et al[44] 25 years ago.
Overall, limited evidence has supported the admi-
nistration of high dose CyA to achieve remission of 
FSGS recurrence with a persistent effect[45,46]. Salomon 
et al[45] reported a remission of recurrent proteinuria 
in 14/17 (82%) of children following administration 
of intravenous CyA (mean period of 21 d; range of 
250-350 ng/mL); after 4 years, 11/17 (64%) patients 
vided major advancements in our knowledge of the 
pathophysiology of FSGS, the treatment remains 
largely empirical. Some interesting preliminary data 
about the use of novel therapies are emerging, but they 
need further evaluation and validation. Therapeutic 
indications for de novo idiopathic and non-idiopathic 
FSGS are even more elusive[29]. 
Here, we summarize the most frequently reported 
available strategies for the management of recurrent 
and de novo FSGS, and suggest the potential benefit 
of these emerging therapies (summarized in Table 1).
Plasma exchange
The adoption of plasma exchange (PE) for treatment 
of FSGS recurrence has been based on the hypothesis 
of the presence of circulating factor(s) that could be 
removed in order to treat or prevent the disease. 
Despite research into this causative factor remaining in 
a status of “cold case”, PE is still a cornerstone in FSGS 
recurrence treatment, since the 1985 report of its first 
positive application by Zimmerman[30]. A systematic 
review by Ponticelli[4] showed that PE promotes partial 
or complete remission in 70% of children and 63% 
of adults with FSGS recurrence. Most of the analyzed 
studies, however, are limited by their retrospective or 
uncontrolled design.
Adoption of PE in a pre-emptive protocol to reduce 
FSGS recurrence has been described by Gohh et 
al[31] in one of the few prospective studies in the 
literature. Ten transplanted patients with FSGS and 
at high risk of recurrence (both children and adults, 
including 5 transplants from living donors and 5 
from deceased donors) were treated with a course 
of 8 PE sessions in the peri-operative period. Seven 
of the patients (including all 4 who received first 
grafts and 3 out of 6 who had prior recurrence) were 
free of recurrence at the end of follow-up (range of 
238-1258 d). The use of pre-emptive PE in a high 
risk pediatric patient who underwent a second living 
kidney transplantation (the first kidney was lost 
due to recurrence) was more recently described by 
Chikamoto et al[32]. The patient had also received a 
2-wk course of Rituximab® (375 mg/m2; 2 doses), 
methylprednisolone (1 mg/kg per day), tacrolimus 
(10 ng/mL) and mycophenolate mofetil (MMF) (600 
mg/m2 per day) before transplantation; at 12 d before 
transplantation, 4 PE sessions were performed. No 
sign of recurrence was found in protocol biopsies at 8 
mo after transplantation.
Canaud et al[33] described positive outcome 
(complete remission at 3 mo after diagnosis) for 10 
patients with FSGS recurrence that had been treated 
with a 9-mo course of intravenous cyclosporine 
(CyA; C0 levels at 200-400 ng/mL), followed by oral 
CyA (C2 levels at 1200-1400 ng/mL), high dose oral 
steroids (1 mg/kg per day for the first 4 wk, then 
progressively tapered) and a course of PE sessions. 
The only patient who experienced recurrence of 
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Table 1  Therapeutic strategies for focal segmental glomerulosclerosis in renal transplantation
Treatment schedule Patients Outcome Adjunctive information
Plasma exchange
   Ponticelli et al[4] Analysis of PE response in 22 
studies
144 patients 
(70 < 18 yr, 77 ≥ 18 yr) 
Partial/complete remission 
of proteinuria in 49/70 (70%) 
children and 49/77 (63%) 
adults
Analysis also includes Canaud 
et al[33] 10 patients
   Gohh et al[31] Prophylactic course of 8 PE 
sessions in the peri-operative 
period in patients at high risk of 
recurrence
10 patients 
(1 < 18 yr, 9 ≥ 18 yr)
7/10 free of recurrence
   Chikamoto et al[32] Prophylactic course of 4 
PE sessions 12 d before 
transplantation in a high risk 
patient
1 patient (< 18 yr) No recurrence after 8 mo Patient also received Rituximab®
 (375 mg/m2; 2 doses), 
methylprednisolone (1 mg/kg 
per day), tacrolimus (10 ng/mL) 
and mycophenolate mofetil (600 
mg/m2 per day) 2 wk before 
transplantation
Glucocorticoids
   Shishido et al[41] Methylprednisolone pulses (20 
mg/kg on three consecutive days 
in weeks 1, 3 and 5) and increasing 
CyA target levels
10 patients (8 < 18 yr, 2 ≥ 18 
yr)
Complete remission in 7/10
CyA
   Canaud et al[33] Intravenous CyA (C0 levels 
between 200-400 ng/mL), followed 
by oral CyA (C2 levels 1200-1400 
ng/mL), high dose oral steroids (1 
mg/kg per day for the first 4 wk, 
then progressively tapered) and a 
course of PE sessions for 9 mo
10 patients (≥ 18 yr) Complete remission of 
proteinuria in 10/10; 
proteinuria relapse in 1/10 
successfully treated with 
Rituximab® (2 doses)
   Ingulli et al[44] Progressive up-titration of CyA 
oral doses
2 patients (< 18 yr) Complete remission in 1; 
partial remission in 1
   Salomon et al[45] Intravenous CyA (through levels: 
250-350 ng/mL)
16 patients (< 18 yr; 1 
re-grafted with a 
subsequent recurrence)
Complete remission in 14/17 
(82%); partial remission in 
2/17 (12%)
   Raafat et al[46] Progressive up-titration of CyA 
oral doses until proteinuria 
reduction/serum creatinine 
elevation (CyA doses from 6 to 25 
mg/kg per day)
16 patients (< 18 yr) Complete remission in 11/16 
(69%); partial remission in 
2/16 (12%)
CYC/MMF
   Kershaw et al[53] CYC (1-2 mg/kg per day, adjusted 
for white blood cell count) for 8-12 
wk
3 patients (< 18 yr) Complete remission in 2/3; 
partial remission in 1/3
   Cheong et al[54] CYC (2 mg/kg per day) + PE 
(10 sessions over 2 wk followed by 
one session per week for 2 mo) 
6 patients (< 18 yr) Complete remission in 3/6; 
partial remission in 3/6
   Dall’Amico et al[55] CYC (2-mo course, 2 mg/kg per 
day) and PE sessions
11 patients (< 18 yr) Complete remission in 9/11 
(persistent remission in 7/9)
   Gipson et al[57] 12-mo course of CYC vs MMF + 
dexamethasone
138 patients [93/168 (67%) 
< 18 yr] 
CyA arm: complete remission 
in 14/72 (19%), partial 
remission in 19/72 (26%)
MMF + dexamethasone arm: 
complete remission in 6/66 
(9%), partial remission in 
16/66 (24%)
Renin angiotensin system blockers
   Freiberger et al[62] Ramipril (10 mg) + candesartan 
(64 mg) + aliskiren (300 mg)
1 patient (≥ 18 yr) Partial remission Patient was previously treated with 
Rituximab® (375 mg/m2; 3 doses) 
and PE without response
Galactose
   Jhaveri et al[64] High galactose diet + 
supplemental powder galactose 
(0.2 g/kg orally 2 times per day) 
one month later
1 patient (≥ 18 yr) Complete remission No apparent response with 
previous treatments including 
Rituximab® (1 g, 2 doses), PE (15 
sessions) and IgEv (2 doses)
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   Robson et al[65] High galactose diet (14 g twice 
daily in patient 1, 10 g twice daily 
in patient 2)
2 patients (≥ 18 yr) Complete remission in 1; 
partial remission in 1
   Sgambat et al[66] High galactose diet (0.2 g/kg per 
dose twice daily orally)
7 patients (< 18 yr) with 
steroid-resistant nephrotic 
syndrome (2/7 with 
recurrent FSGS)
Reduction in permeability 
factor without effect on 
proteinuria values
Anti-TNF-a agents
   Leroy et al[69] Infliximab (3 mg/kg twice 
monthly)
1 patient (< 18 yr) Complete remission No apparent response with 
previous treatments including 
reinforced immunosuppression, 
CyA (5 mg/kg per day in 
continuous i.v. perfusion) followed 
by oral high dose CyA (10 mg/kg 
per day), methylprednisolone 
pulses followed by high dose oral 
prednisone (60 mg/1.73 m2 per 
day), MMF (600 mg/1.73 m2 per 
day) switch to cyclophosphamide 
(100 mg/d, interrupted for 
hematologic toxicity) and PE (15 
sessions within 1 mo)
   Bitzan et al[70] Etanercept (twice weekly) 1 patient (< 18 yr) Partial remission
Rituximab®
   Pescovitz et al[28] Rituximab® (6 doses, 375 mg/m2) 1 patient (< 18 yr) Complete remission
   Hristea et al[74] Rituximab® (2 doses, 375 mg/m2) 1 patient (≥ 18 yr) Complete remission Patient also received a short course 
of oral cyclophosphamide 
(100 mg/d, days 22-40) and 3 
additional PE sessions 
(days 34, 39, 49)
   Gossmann et al[75] Rituximab® (2 doses, 375 mg/m2) 1 patient (≥ 18 yr) Complete remission
   Fornoni et al[21] Rituximab® within 24 h after 
surgery (1 dose, 375 mg/m2) in 
patients at high risk of recurrence
41 patients (14 controls vs 27 
treated) 
Nephrotic proteinuria within 
1 mo in 7/27 patients in 
Rituximab® group vs 9/14 
patients in control group 
(P < 0.005)
Patient mean age: 12.3 ± 5.2 yr 
(control group), 15.0 ± 5.5 yr 
(Rituximab® group)
   Audard et al[76] Rituximab® induction in patients 
at high risk of recurrence 
(first graft lost due to recurrence) 
4 patients (≥ 18 yr) No evidence of significant 
proteinuria at the end of 
follow-up
Single dose of 75 mg/m2 in 2/4 
patients, repeated dose of 375 
mg/m2 on day 7 in the remaining 
2 patients; associated PE sessions 
(6 and 15, respectively) in 2/4 
patients
   Hickson et al[77] Rituximab® (375 mg/m2; 2-4 doses) 
+ PE
4 patients (3 < 18 yr, 1 ≥ 18 
yr)
Complete remissions in 4/4 
patients
Early Rituximab® treatment in 
3/4 (7–63 d post-transplantation), 
late treatment in 1/4 (982 d post-
transplantation during a prolonged 
PE-dependent remission)
   Dello Strologo 
   et al[78]
Rituximab® (375 mg/m2; 1-4 doses) 
+ PE
6 patients (4 < 18 yr; 2 ≥ 18 
yr)
Complete remission in 3; 
partial remission in 2; no 
response in 1
1/7 patients received one dose, 
4/7 patients received 2 doses, and 
1/7 received 4 doses; 1/7 patients 
experienced a severe reaction 
during first infusion and was 
excluded from the analysis
   Tsagalis et al[79] Rituximab® (1 g, 2 doses) + PE 4 patients (2 < 18 yr; 2 ≥ 18 
yr)
Complete remission in 2; 
partial remission in 2
   Cho et al[80] Rituximab® (100 mg, 1 dose) 1 patient (≥ 18 yr) Complete remission
   Yabu et al[87] Rituximab® + PE 4 patients (≥ 18 yr) No response or proteinuria 
relapse after Rituximab®
Rituximab® schedule: 1 g, 2 doses 
in 1/4; 375 mg/m2, 4 doses in 1/4; 
375 mg/m2, 6 doses in 2/4
   Kumar et al[117] Rituximab® + PE 8 patients (< 18 yr) Complete remission in 2/8; 
partial remission in 4/8; no 
response in 2/8
Rituximab® schedule: 375 mg/m2, 
4 doses in 4/8; 375 mg/m2, 1 doses 
in 1/8; 375 mg/m2, 3 doses in 1/8; 
375 mg/m2, 8 doses in 1/8; 375 
mg/m2, 10 doses in 1/8
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   Park et al[88] Rituximab® (375 mg/m2, 1 or 2 
doses) before transplantation with 
or without PE
9 patients PE ± Rituximab® 
treated (Rituximab® group) 
vs 18 patients (control 
group) 
No statistical difference in 
the prevention of recurrence 
between PE ± Rituximab® 
group (2/9, 22%) vs control 
group (5/18, 28%)
Rituximab® schedule: 375 mg/m2, 
1 dose for desensitization in high 
risk patients; 375 mg/m2, 2 doses in 
ABO-incompatible transplantation; 
data not shown for recurrence 
prevention
   Kamar et al[89] Rituximab® (2-4 doses, 375 mg/m2) 2 patients (≥ 18 yr) Complete remission in 1 
patient; no response in 1 
patient
Rituximab® schedule: 75 mg/m2, 
2 doses in the first patient (a 
supplemental dose was repeated 
after proteinuria relapse in 
association with PE sessions, 
achieving a new complete 
remission); 375 mg/m2, 4 doses in 
the second patient
   El-Firjani et al[90] Rituximab® (6 doses, 375 mg/m2) 1 patient (≥ 18 yr) No response
   Apeland et al[81] Rituximab® (3 doses, 375 mg/m2) 1 patient (≥ 18 yr) Complete remission
   Grenda et al[82] Rituximab® (4 doses, 375 mg/m2) 1 patient (< 18 yr) Complete remission
   Sethna et al[83] Rituximab® (4 doses, 375 mg/m2) 
+ PE
4 patients (< 18 yr) Complete remission in 3/4; 
partial and unsustained 
response in 1/4
Proteinuria relapse in 1/3 patients 
with complete remission response 
to PE sessions intensification + an 
adjunctive dose of Rituximab®
   Prytula et al[91] Rituximab® (1-5 doses, 375 mg/m2) 14 patients (< 18 yr) Complete remission in 6/14; 
partial remission in 3/14; no 
response in 5/14
   Stewart et al[92] Rituximab® (4 doses, 375 mg/m2) 1 patient (< 18 yr) Complete remission
   Nozu et al[84] Rituximab® (4 doses, 375 mg/m2) 1 patient (< 18 yr) Complete remission Treatment was adopted after 
a diagnosis of post-transplant 
lymphoproliferative disorder 
   Nakayama et al[85] Rituximab® (1-2 doses, 375 mg/m2) 2 patients (< 18 yr) Complete remission in 2 
patients
One patient received a single dose; 
the other patient, after achieving a 
complete remission with the first 
dose, experienced a proteinuria 
relapse and rapidly responded to a 
second Rituximab® dose
   Marks and 
   McGraw[93]
Rituximab® (4 doses, 375 mg/m2 in 
one case; 2 doses 750 mg/m2 in the 
other one)
2 patients (< 18 yr) No response
   Bayrakci et al[86] Rituximab® (4 doses, 375 mg/m2) 1 patient (< 18 yr) Complete remission
   Rodríguez-Ferrero 
   et al[94]
Rituximab® (4 doses, 375 mg/m2) 3 patients (≥ 18 yr) Partial remission in 2/3; no 
response in 1/3
CTLA4-Ig (considered as the prevalent treatment)
   Yu et al[103] Abatacept 4 patients (2/4 < 18 yr, 
2/4 ≥ 18 yr) with FSGS 
recurrence; 1 patient (≥ 18 
yr) with FSGS on native 
kidneys
Complete remission in 2/5; 
partial remission in 3/5
Patients 1 and 2 received a single 
dose; patients 3 and 4 received 2 
doses; patient 5 (the only one with 
FSGS on native kidneys) received 
3 doses (days 1, 15, 30) and a dose 
monthly thereafter
   Alachkar et al[104] Abatacept (1 dose; 10 mg/kg) in 
patient 1; belatacept (3 doses 10 
mg/kg or continuative treatment) 
in patients 2-5
5 patients (≥ 18 yr) No response
   Garin et al[105] Abatacept (1 or 2 doses; 10 mg/kg) 
or belatacept (16 doses 5 mg/kg) 
5 patients (2/5 < 18 yr with 
minimal change in disease 
or FSGS on native kidneys; 
3/5 with FSGS recurrence 
(1/3 < 18 yr, 2/3 ≥ 18 yr)
Partial response in minimal 
change disease patient; 
no response in primary 
FSGS patient; partial 
remission in 1/3 with 
FSGS recurrence (abatacept 
treated); no response in 2/3 
(abatacept/ belatacept treated 
respectively)
Patients 1, 2 and 4 received 2 
abatacept doses: patient 3 received 
1 abatacept dose; patient 5 was 
treated with belatacept
   Alkandari et al[106] Abatacept (3 doses; 10 mg/kg) 1 patient (< 18 yr) No response
   Grellier et al[107] Belatacept (days 1, 15, 30 and 
monthly thereafter, 5 mg/kg)
5 patients (≥ 18 yr) Partial response in 2/5; no 
response in 3/5 (no worsening 
in proteinuria values pre- and 
post-belatacept therapy in 
1/3)
PE: Plasma exchange; CyA: Cyclosporine; CYC: Cyclophosphamide; FSGS: Focal segmental glomerulosclerosis; TNF-a: Tumor necrosis factor-alpha; MMF: 
Mycophenolate mofetil.
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had achieved sustained remission. In a second series, 
remission was induced in 13/16 patients (81%), which 
also included PE sessions for 4 of the cases; CyA doses 
were from 6 to 25 mg/kg per day[46]. At the latest 
follow-up (range of 10 mo to 12 years), 11/13 (84%) 
patients had a functioning allograft. It is noteworthy to 
mention that in this study, as in the studies by Canaud 
et al[33] and Chikamoto et al[32], the CyA treatment was 
combined with PE sessions.
The mechanism by which CyA might decrease 
proteinuria has been elucidated recently. Briefly, CyA 
has been shown to act by means of a direct effect on 
the cytoskeleton via dephosphorylation of synaptopodin, 
a crucial stabilizer of podocyte actin cytoskeleton, rather 
than through an immunosuppressive activity such 
as inhibition of T cells[47,48]. According to these clinical 
evidence, it was postulated that the anti-proteinuric 
effect had been observed only with high dose CyA 
because the hypercholestorelemic state induced by NS 
limits the CyA active fraction[49].
Currently, the option of CyA therapy in FSGS is 
more frequently used in combined-therapy regimens. 
The long-term safety/efficacy ratio of such a therapy, 
however, remains to be confirmed by study, which is 
of particular importance in light of the severe toxicities 
associated with high dose CyA.
Cyclophosphamide and mycophenolate mofetil
Cyclophosphamide (CYC) is an alkalizing agent that 
inhibits cell DNA duplication, leading to cell death. It 
is active both on resting and dividing lymphocytes[50]. 
Anecdotal experiences with CYC therapy (2 mg/kg 
per day) reported achievement of partial or complete 
remission in patients with FSGS on native kidneys and 
also in steroid-dependent patients; however, no benefit 
was found in steroid-resistant patients[51,52]. 
In FSGS recurrence, Kershaw et al[53] treated 
3 pediatric patients with CYC (1-2 mg/kg per day, 
adjusted for white blood cell count) for 8-12 wk and 
obtained two complete remissions and one partial; 
the patient with the longest follow-up (125 mo) ex-
perienced two additional relapses, each of which were 
treated successfully with pulse intravenous steroids. 
A more recent report described a series of 6 patients 
with FSGS recurrence all of whom were treated with 
a combination of CYC and PE (10 sessions over 2 
wk, followed by 1 session per week for 2 mo), with 
complete remission being achieved in 3 of the patients 
and partial remission in the other 3[54]. A second case 
series described 11 pediatric patients with FSGS re-
currence who were treated with a 2-mo course of 
CYC (2 mg/kg per day) and PE sessions, with initial 
remission being achieved in 9/11 and with 7/9 being 
free of disease at the last follow-up (32 ± 15 mo)[55].
MMF inhibits the inosine monophosphate dehydro-
genase-mediated reduction of T and B lymphocyte 
proliferation. Gbadegesin et al[56] suggested MMF for 
treatment of steroid-dependent/resistant FSGS on 
native kidneys. Subsequently, a randomized controlled 
trial including 138 patients (both children and adults) 
with primary FSGS compared CyA and MMF plus 
dexamethasone, but no difference was observed in 
complete or partial remission rates after 52 wk of follow-
up and both groups showed poor outcome (remission 
in 46% vs 33%, respectively)[57]. At the present time, 
as reported by Lau et al[58], no randomized controlled 
trial has yet to demonstrate the efficacy of MMF in 
association with other therapies or as a single agent in 
FSGS treatment on native or transplanted kidneys.
Renin angiotensin system blockers
Renin angiotensin system (RAS) blockers have an 
important role in blood pressure control, but they also 
have anti-proteinuric and systemic anti-inflammatory 
effects[59]. RAS inhibition represents an important 
therapeutic strategy in proteinuric glomerular disease 
as FSGS, for either recurrent or de novo types.
Despite some reports having suggested RAS 
blockers as effective therapeutics for this disease[60,61], 
the association of these drugs with other therapies 
limits a final judgment on their real effect as a single 
drug. Freiberger et al[62] reported a favorable outcome 
after the use of a triple RAS blockage [angiotensin-
converting enzyme (ACE) inhibitor, angiotensin receptor 
(blocker) antagonist (ARB), and renin inhibitor] in 
a transplanted patient with FSGS recurrence; since 
PE and Rituximab® treatment produced no apparent 
benefits in the patient previously, a late response to 
this treatment may not be excluded “a priori”.
It is noteworthy that a close monitoring of serum 
creatinine and potassium levels is essential in all 
subjects treated with RAS blockers, especially when all 
these drugs are prescribed together and even more so 
when renal function is suboptimal.
ANECDOTAL THERAPIES 
Galactose
The potential effect of galactose on glomerular 
permeability and proteinuria was firstly hypothesized 
by Savin et al[63], stating that sucrose binds with high 
affinity and inactivates the supposed “permeability 
factor”, thereby facilitating its plasma clearance.
Jhaveri et al[64] described a patient with severe 
recurrent FSGS (massive proteinuria of 37 g/d at day 2 
after transplantation) who had been previously treated 
with PE, intravenous immunoglobulin and Rituximab®, 
and achieved complete remission of proteinuria after 
receipt of a high galactose diet and supplemental oral 
galactose (0.2 g/kg, two times per day). As for other 
case series mentioned before, the role played by 
galactose in disease remission vs the role of previous 
treatment is indistinguishable. More recently, Robson 
et al[65] also reported a favorable outcome (1 complete 
and 1 partial response) in 2 patients with FSGS 
recurrence treated with high galactose diet. Sgambat 
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et al[66] reported in a recent case series a reduction in 
permeability factor activity in 7 pediatric patients with 
steroid-resistant NS (2/7 with recurrent FSGS) treated 
with high galactose diet (0.2 g/kg, twice daily), without 
any significant improvement in proteinuria values.
Anti-tumor necrosis factor-alpha agents
The tumor necrosis factor-alpha (TNF-a) signaling 
pathway is involved in the development of both NS 
and FSGS, as evidenced by elevated levels of TNF-a 
detected in plasma and urine obtained from patients 
with FSGS[67] and increased glomerular permeability to 
TNF-a observed in vitro[68]. 
At the present time, very few cases of FSGS have 
been treated with anti-TNF-a agents. Leroy et al[69] 
reported a favorable outcome (complete remission) 
for a 15-year-old patient with recurrent FSGS that 
was presumably resistant to other treatments (in-
creased immunosuppressant dose, PE, intravenous 
immunoglobulin, high dose steroids, CyA, and CYC) 
after administration of an anti-TNF-a blocker (firstly 
infliximab, then etanercept). Bitzan et al[70] showed 
that plasmapheresis effluent or fresh plasma (obtained 
from a child with recurrent FSGS and from two children 
with primary FSGS) caused cytoskeleton disturbance 
on podocyte culture. In detail, the plasma from the 
patient with FSGS recurrence activated b3 integrin and 
dispersed focal adhesion complexes, and this effect 
was reversed by pre-incubation with antibodies against 
TNF-a or either of the two TNF-a receptors. Following 
this study’s observation, the patient who was plasma 
resistant was treated firstly with Etanercept and 
then with Infliximab, which ultimately led to partial 
remission of the disease.
NOVEL THERAPEUTIC OPTIONS 
Rituximab®
Rituximab® is a chimeric monoclonal antibody that 
recognizes CD20 antigen on B lymphocytes. This 
agent has several unlabeled applications in the field of 
kidney transplantation; it has been successfully applied 
to reduce anti-donor ABO or HLA antibodies[71] and 
to treat acute humoral rejection of the graft[72], post-
transplant lymphoproliferative diseases[73], and also 
some recurrent/de novo glomerulonephritis.
Rituximab® treatment also has a long history 
of interest in its potential as a therapeutic option 
for idiopathic NS before and after transplantation. 
However, after the initial reports about its favorable 
use in FSGS recurrence were published in 2006 and 
2007[28,74,75], conflicting results were reported by other 
studies in the literature. Currently, Rituximab® may 
be adopted as a preventive therapeutic approach to 
reduce FSGS recurrence rate, or as a treatment of 
FSGS recurrence.
The use of Rituximab® as a prevention strategy 
derives from two retrospective studies[21,76]. In the first, 
Fornoni et al[21] investigated 27 kidney transplanted 
patients at high risk for FSGS recurrence and showed 
that use of Rituximab® in the perioperative period (375 
mg/m2 within 24 h after the kidney transplantation) 
was associated with a lower incidence of post-
transplant proteinuria and with stabilization of GFR at 
the 12 mo follow-up. This study also demonstrated 
for the first time that Rituximab® operates in a B 
cell-independent manner; sera obtained from FSGS 
recurrent patients caused a down-regulation of 
SMLPD-3b, a protein involved in regulation of podocyte 
cytoskeleton, and this phenomenon was prevented by 
pre-treatment with Rituximab® through direct binding.
Audard et al[76] observed the absence of a clinical 
FSGS recurrence (not biopsy proven) in 4 patients 
who received Rituximab® (375 mg/m2) in their 
induction protocol for a second kidney transplant (first 
kidney lost due to a recurrent disease). Nevertheless, 
the short follow-up (12-54 mo), the difference in 
Rituximab® schedule (a single administration in 2/4 
patients and 2 doses in the other 2 patients), and PE 
adoption in 2/4 patients partially limit the significance 
of this uncontrolled study.
To date, Rituximab® has been widely used, alone 
and in combination protocols, as a treatment for 
recurrent FSGS in cases of incomplete remission, 
PE dependence, or as a first-line therapy in specific 
patient subsets. Despite successful results having been 
obtained[77-86], other studies have shown a transient or 
even absent response to Rituximab®[62,87-94] (Table 1).
Abatacept
Abatacept is a biologic agent, specifically the CTLA4-
Ig recombinant fusion protein derived from the 
extracellular portion of CTLA4-Ig and genetically 
fixated to the high and constant portion of the IgG1 
immunoglobulin. Its effect is exerted by interfering 
with lymphocyte co-stimulation[95,96] upon binding to 
the APC protein ligands B71 (CD80) or B72 (CD86) 
and displacing their T cell counterpart or CD28[97]. In 
some experimental models of organ transplantation, 
the systemic administration of CTLA4-Ig effectively 
dampened the immune response, preventing ex-
perimental acute and chronic rejection and resulting 
in prolonged graft survival and tolerance[98-100]. On the 
basis of these findings, different biological T cell co-
stimulation blockers became the subject of clinical 
trials. A high affinity variant of CTLA4-Ig, named 
LEA29Y (belatacept, Nulojix®; Bristol-Myers Squibb 
Pharma, Uxbridge, United Kingdom), has been 
developed and was awarded approval by the Federal 
Drug Administration (FDA) in 2011 for prophylactic use 
for organ rejection in adult kidney recipients[101].
Abatacept was approved by the FDA in 2005 
for the treatment of rheumatoid arthritis and active 
juvenile idiopathic arthritis[102], and quite recently 
has been proposed as a new treatment strategy for 
FSGS recurrence. Yu et al[103] reported a positive 
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outcome in 4 patients (2 children) affected by early 
and Rituximab®-resistant FSGS recurrence and in 1 
patient with glucocorticoid-resistant primary FSGS on 
native kidneys. All these patients received abatacept, 
at a dose between 250 mg/d and 500 mg/d, the 
most commonly used dose for rheumatoid arthritis 
treatment. Before using abatacept, PE sessions were 
also performed in all 4 patients with FSGS recurrence, 
while the patient with primary disease on native 
kidneys received an immunosuppressive treatment 
composed of prednisone and CyA, with tacrolimus 
applied as a second line therapy. All patients achieved 
and maintained a significant proteinuria regression 
after 10-48 mo of follow-up. The authors suggested 
that this response was directly correlated with the 
B71-positive immuno-stained podocytes found in 
the kidney-biopsy specimens, because B71 may be 
expressed on the podocyte surface in some proteinuric 
conditions such as FSGS, thereby altering cytoskeleton 
organization, a condition that is known to be abrogated 
by abatacept.
Nevertheless, other studies of patients with FSGS 
recurrence have shown a slight/absent response after 
treatment with CTLA4-Ig[104-107], despite the fact that in 
some of these cases belatacept (able to bind B71 with 
an higher affinity than abatacept) was adopted. 
Human allogeneic bone marrow mesenchymal stem 
cells
The use of bone marrow mesenchymal stem cells (BM-
MSCs) has been reported to reduce kidney injury in 
different experimental models of kidney disease[108-111]. 
Ma et al[111] showed in a well-established murine 
model of FSGS (adriamycin nephropathy) that human 
umbilical mesenchymal stem cells (HuMSCs) may 
improve kidney fibrosis and modulate the inflammatory 
response. Recently, BM-MSCs have been demonstrated 
as effective treatment for a wide range of immuno-
mediated diseases[112-114].
Belingheri et al[115] reported successful application of 
their innovative approach with BM-MSCs in a 13-year-
old kidney transplanted patient who had developed an 
immediate biopsy proven FSGS recurrence after renal 
transplantation and who was non-responsive to PE 
and Rituximab® (2 doses). The patient had received 
allogeneic BM-MSCs infusions (6 doses, according to 
the most commonly adopted protocol for treatment 
of graft vs host disease) at months 7, 10 and 14 after 
transplantation and at month 5 after Rituximab® 
administration. Remission of proteinuria was achieved 
after three BM-MSCs infusions, and at the last follow-
up (22 mo) both renal function and proteinuria values 
were stable. The treatment appeared as well tolerated, 
and no adverse events were noted.
DISCUSSION
In the field of glomerulonephritis, primary FSGS 
portends one of the most unpredictable and variable 
outcomes, carrying one of the highest recurrence 
rates for transplanted kidneys (from 30% to 50% 
in patients with a history of primary FSGS on native 
kidneys)[4-6]. FSGS recurrence also remains a “clinical 
drama”, with almost 50% of allografts lost at 5 years 
and having a HR of 2.03 compared to other kinds of 
recurrent glomerulonephritis[8]. Despite the proposal 
of multiple therapeutic approaches over time, none 
has yet emerged as the resolutive option, either for 
the recurrent or de novo types of FSGS; yet, none 
has been disproven or ruled out and each has several 
aspects that still need to be studied.
Indeed, PE is still widely applied as FSGS recurrence 
treatment and as a pre-emptive strategy, despite the 
absence of controlled trials. Nevertheless, a course 
of PE treatment is widely used and recommended, 
titrated according to the clinical/histological response 
as proposed by Ponticelli[4], even if it remains difficult 
to determine when to start and when to stop and 
which schedule of PE sessions is best. Interpreta-
tion of the literature data for PE is difficult, partially 
due to the existence of publication bias, in which 
positive outcomes of some cases may lead to an 
overestimation of treatment efficacy. In addition, 
the reports on PE often describe studies in which the 
therapy is applied as part of a combination regimen 
that includes other disease-modifying treatments 
(i.e., corticosteroids, Rituximab®, CyA), complicating 
the interpretation of results. Besides, few prospective 
studies are available and none of them used a control 
group study design.
On the other hand, application of high dose CyA 
must be carefully considered on the basis of drug-
related toxicities, especially nephrotoxicity. Most of 
the CyA studies have thus far only included pediatric 
patients or living-related donors, two populations 
that are more prone to tolerating high dose CyA. To 
the contrary, when patients are adult recipients of a 
kidney from a deceased marginal donor, nephrotoxicity 
from high dose CyA could be a problematic issue. The 
previous reported considerations for PE regarding its 
frequent association with other treatments capable of 
strengthening its effect are also applicable to CyA (see 
the study by Canaud et al[33] for an example).
The paucity of data on CYC/MMF adoption for 
treatment of recurrent FGSS represents another limitation 
to using the collective literature to draw conclusions 
about their utility in clinical practice. On the other 
hand, Rituximab® is one of the most interesting agents 
proposed to date for treatment of FSGS recurrence; 
but, again, several limitations lie in the related literature, 
including the use of a surrogate end-point of disease 
activity (i.e., clinical/not histological definition of recurrent 
FSGS in the study by Fornoni et al[21]), short follow-
up[76,77], and evidence of absence of positive effects[62,87-94]. 
Furthermore, the Rituximab® dose is another matter of 
debate, and the question remains: Should the classic 
scheme borrowed from hematologic protocols (4 doses 
of 375 mg/m2 each) or a shorter regimen (titrated to the 
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minimal level necessary to obtain B cell depletion) be 
adopted? Another first line question involves when the 
infusion should be performed: As a pre-emptive therapy 
soon after surgery, in cases at high risk of recurrence, 
or at the time of recurrence? Although, Rituximab® 
portends some serious side effects, increasing the risk of 
opportunistic infections in transplanted patients during 
the entire time of its blockage of the immune response. 
Araya et al[116] reported side effects in about 10% of cases 
(1 case each of neutropenia, severe anaphylactic reaction, 
BK virus nephropathy, and severe sepsis). Kumar et 
al[117] observed a significant rate of severe complications 
(3/8 patients), ranging from Rituximab®-associated 
lung injury, acute tubular necrosis, and central nervous 
system malignancy.
The ACEs or ARBs should be considered as ad-
juvant therapy, especially when other therapies have 
failed or are not applicable. However, their use may be 
contraindicated by low GFR and risk of hyperkalemia.
Considering the so-called “anecdotal therapies” 
(galactose, anti-TNF-a agents), their place in the 
armamentarium for FSGS treatment in renal transplant 
is very small in current times, but they could be 
considered for use in rare conditions as a salvage 
therapy. Considering the more innovative treatments, 
BM-MSCs represent a promising treatment[115]. 
Nevertheless, the results reported in the literature to 
date need to be evaluated on the basis of the possible 
influence of previous treatments received by the 
patients, especially considering a delayed effect of 
Rituximab® administration, and the natural evolution of 
the disease, which is often unpredictable. 
On the other hand, safety of BM-MSCs remains 
an open question. On the basis of literature data, 
auto- and allo-MSCs may interfere with the immune 
response in a non-defined and unpredictable manner. 
For example, Reinders et al[118] found auto-MSCs 
infusion for the treatment of acute rejection to be 
associated with opportunistic viral infection in 3/6 
patients. Allo-MSCs may also induce the production 
of anti-donor antibodies, as observed in some animal 
models[119]. Nevertheless, a strong limitation to the 
adoption of cell therapies is the unknown proneoplastic 
effect, secondary to a direct (but also indirect) MSCs 
dedifferentiation[120,121].
A possible way to reduce or abrogate the risk 
deriving from MSCs infusion is to promote podocyte 
regeneration. In some experimental models, native 
parietal epithelial cells (PECs) have been shown to have 
the potential to migrate to the glomerular tuft after 
kidney injury, acquiring a phenotype and a morphologic 
appearance similar to a differentiated podocyte and 
thereby mitigating the damage[122,123]. On the other 
hand, PECs have also been associated with glomerular 
injury and sclerosis[124], so a definitive consideration 
about their role and potential therapeutic applications is 
far from being defined.
The therapeutic role of co-stimulatory molecule 
blockades is emerging for some glomerulonephritis 
on native kidneys (e.g., lupus nephritis)[125]. Recently, 
abatacept was associated with interesting results in 
proteinuria reduction in a small case series of FSGS 
recurrent patients[103]. Nevertheless, a limitation 
related to the histological findings reported is intrin-
sically linked with the efficacy, because all positive 
results were obtained only in patients with positive B71 
staining on renal biopsy and the negative outcomes 
were reported for patients without this staining pattern 
on renal specimens[101]. In addition, the absence of 
response after belatacept use[99,100,102] (abatacept’s 
“twin drug” with a higher affinity to the B71 receptor) 
remains an open issue.
In conclusion, no treatment guideline can be pro-
posed at this time to address FSGS in renal transplan-
tation. In our opinion, waiting for improvement in 
podocyte biology knowledge and taking the perspective 
that therapeutic protocols should be tailored to the 
single patient will help to optimize the risk/benefit 
balance. Protocol biopsy is a useful strategy chosen 
during the difficult decision-making process involved 
in cases possibly needing interruption of on-going 
targeted therapies (maybe with the only exception 
of RAS blockers). We suggest, as a first line option, 
the use of Rituximab® at a single dose of 375 mg/m2 
(also for induction protocols in patients at high risk of 
recurrence) with a close monitoring of CD20+ count, 
that will be applied in combination with steroids and a 
PE course. The initial schedule could be 5-10 sessions 
on alternating days, followed by tapering to a 1/wk 
or less schedule according to the patient’s clinical 
response. The crucial issue is determining the right time 
to stop PE after proteinuria disappearance. 
Therapy for FSGS in renal transplantation remains 
an unmet clinical need. Randomized-controlled clinical 
trials are highly important to resolve this issue and 
necessary to elucidate the correct approach and the 
real potentiality of the more recently proposed drugs.
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